Recent Updates
Recently added Catalysts
CRMD Positive Sentiment Score: 70/100

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

Monday, November 4, 2024 1 min read
Key Takeaway: CorMedix Inc. (Nasdaq: CRMD) has announced its participation in the upcoming Truist Securities BioPharma Symposium in New York City, scheduled for November 7, 2024. The company focuses on developing and commercializing therapeutic products for serious health conditions, specifically highlighting its FDA-approved product, DefenCath, which launched in 2024. CorMedix aims to expand the use of DefenCath as a catheter lock solution in various patient populations. This engagement at the symposium may provide an opportunity for greater exposure and networking within the biopharma industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • CorMedix is participating in a prominent BioPharma symposium, enhancing visibility.
  • The company has successfully launched its product DefenCath in both inpatient and outpatient settings.
  • DefenCath received FDA approval, indicating regulatory confidence in the product.

Full Press Release Details

BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma Symposium, taking place in New York City on Thursday, November 7, 2024.
Truist Securities BioPharma Symposium
Date: Thursday, November 7, 2024
Format: 1x1 meetings
Location: Lotte New York Palace Hotel, New York, NY
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
daniel@lifesciadvisors.com

Frequently Asked Questions

When is the Truist Securities BioPharma Symposium?

The symposium will take place on November 7, 2024.

Where will the BioPharma Symposium be held?

It will be held at Lotte New York Palace Hotel, New York, NY.

What is CorMedix Inc. focused on?

CorMedix develops therapeutic products for life-threatening diseases.

What is DefenCath® approved for?

DefenCath® is approved for preventing and treating life-threatening conditions.

When was DefenCath launched commercially?

DefenCath was launched in April 2024 for inpatient and July 2024 for outpatient.

Tags: CRMD Viatris Investor Conferences Healthcare CorMedix DefenCath BioPharma Symposium FDA approval
Last updated: Nov 4, 2024